Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC) is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and c-ros oncogene 1 (ROS1) mutations are now used to guide specific ant...
Main Authors: | Kim Tam Bui, Wendy A. Cooper, Steven Kao, Michael Boyer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2077-0383/7/8/192 |
Similar Items
-
Mutation of the BRAF Genes in Non-small Cell Lung Cancer
by: Zhimin HUANG, et al.
Published: (2012-03-01) -
Translational Research on Epidermal Growth Factor Receptor Gene Mutations in Targeted Therapy for Patients with Advanced Non-Small Cell Lung Cancer
by: Xiao-yan WANG, et al.
Published: (2015-12-01) -
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
by: Rui Kitadai, et al.
Published: (2019-02-01) -
Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer
by: Alia Daoud, et al.
Published: (2017-09-01) -
Biomarker Testing for People With Advanced Lung Cancer in England
by: Jana B. Adizie, MbChB., MRCP, MD, et al.
Published: (2021-06-01)